Aveo’s Tivozanib Falls On Survival Data, Study Design Flaws
This article was originally published in The Pink Sheet Daily
Executive Summary
In a lopsided vote, FDA’s Oncologic Drugs Advisory Committee said the renal cell carcinoma drug has not been shown to have a favorable benefit/risk profile due to a negative trend in overall survival and flaws in the design and conduct of the sole pivotal trial.